Article Versions Notes

Ridgway H, Apostolopoulos V, Moore GJ, Gadanec LK, Zulli A, Swiderski J, Tsiodras S, Kelaidonis K, Chasapis CT, Matsoukas JM. Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses. Viruses. 2024; 16(11):1776. https://doi.org/10.3390/v16111776

Ridgway, Harry, Vasso Apostolopoulos, Graham J. Moore, Laura Kate Gadanec, Anthony Zulli, Jordan Swiderski, Sotirios Tsiodras, Konstantinos Kelaidonis, Christos T. Chasapis, and John M. Matsoukas. 2024. "Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses" Viruses 16, no. 11: 1776. https://doi.org/10.3390/v16111776

Ridgway, H., Apostolopoulos, V., Moore, G. J., Gadanec, L. K., Zulli, A., Swiderski, J., Tsiodras, S., Kelaidonis, K., Chasapis, C. T., & Matsoukas, J. M. (2024). Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses. Viruses, 16(11), 1776. https://doi.org/10.3390/v16111776